Actuate Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
- Conditions
- Salivary Gland CarcinomaAdenoid Cystic CarcinomaSalivary Gland CancerSalivary Gland Neoplasms
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- Actuate Therapeutics Inc.
- Registration Number
- NCT04832438
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9-ING-41 in Pediatric Patients With Refractory Malignancies.
- Conditions
- Cancer PediatricPediatric CancerPediatric Brain TumorRefractory CancerRefractory TumorPediatric MeningiomaNeuroblastomaNeuroblastoma RecurrentRefractory NeoplasmPediatric Lymphoma
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04239092
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Actuate 1901: 9-ING-41 in Myelofibrosis
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04218071
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Georgia Cancer Center, Augusta, Georgia, United States
9-ING-41 in Patients with Advanced Cancers
- Conditions
- CancerPancreatic CancerPancreatic AdenocarcinomaNeoplasm, BreastNeoplasms PancreaticMalignanciesMalignancies MultipleBone CancerPancreatic NeoplasmsNeoplasm Metastasis
- Interventions
- Drug: Nab paclitaxel.Drug: Doxorubicin.Drug: Carboplatin.Drug: Paclitaxel.
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT03678883
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
News
Elraglusib Granted FDA Rare Pediatric Disease Designation for Ewing Sarcoma
Actuate Therapeutics' elraglusib, a GSK-3β inhibitor, receives FDA Rare Pediatric Disease Designation for Ewing sarcoma (EWS) treatment.